相关临床试验
49
31 进行中
药物批准
2
批准总数
监管机构
2
监管机构数
成立时间
2008
进行中（未招募）
31
63.3%
Approved For Marketing
1
2.0%
已完成
11
22.4%
招募中
1
2.0%
终止
5
10.2%
- DelveInsight's 2025 pipeline report reveals over 165 companies are developing 170+ investigational therapies for triple-negative breast cancer (TNBC), spanning from preclinical to Phase III trials. - Key emerging therapies include trilaciclib (G1 Therapeutics), olaparib (AstraZeneca), and patritumab deruxtecan (Daiichi Sankyo/Merck), with several receiving breakthrough therapy designations and showing promising clinical results. - Recent clinical milestones include Akeso's ivonescimab receiving breakthrough therapy designation from China's NMPA and Kazia Therapeutics reporting an immune-complete response in a stage IV TNBC patient treated with paxalisib combination therapy. - The TNBC therapeutics market is expected to experience substantial growth driven by rising incidence rates, improved diagnostics, increased awareness, and the anticipated introduction of novel treatment options.
- DelveInsight's 2025 report reveals over 165 companies are developing 170+ pipeline therapies for triple-negative breast cancer, driven by rising disease prevalence and growing research investments. - Recent clinical milestones include Cardiff Oncology's positive Phase 1b data for onvansertib plus paclitaxel, Akeso's breakthrough therapy designation for ivonescimab combination, and multiple Phase III studies initiated by AstraZeneca and others. - Leading pipeline candidates include trilaciclib (G1 Therapeutics), olaparib (AstraZeneca), and patritumab deruxtecan (Daiichi Sankyo/Merck), representing diverse therapeutic approaches from CDK4/6 inhibitors to antibody-drug conjugates. - The TNBC therapeutics market is expected to undergo substantial growth due to improved diagnostics, increased awareness, higher healthcare spending, and anticipated launches of innovative treatments.
- Genor Biopharma Holdings Ltd. received China National Medical Products Administration (NMPA) approval for Lerociclib (GB491), a novel CDK4/6 inhibitor for advanced breast cancer treatment. - The oral bioavailable drug targets hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer in adult patients. - Lerociclib will be used in combination with aromatase inhibitors as initial therapy or with fulvestrant following endocrine therapy progression. - The approval represents a significant milestone resulting from successful collaboration between Genor Biopharma and G1 Therapeutics Inc.
• The mTNBC pipeline includes over 12 drugs from 10+ companies, targeting novel approaches to improve treatment outcomes for this aggressive breast cancer. • Trilaciclib, a CDK4/6 inhibitor by G1 Therapeutics, is in Phase III trials to preserve bone marrow and immune function during chemotherapy in mTNBC patients. • Olinvacimab, an anti-angiogenic antibody by PharmAbcine/Merck, is in Phase II trials, blocking the VEGF/VEGFR2 pathway to inhibit tumor growth and metastasis. • Emerging therapies focus on intravenous, subcutaneous, and oral routes of administration, with molecule types including monoclonal antibodies and small molecules.
- Danish pharmaceutical company Pharmacosmos has finalized its acquisition of US-based G1 Therapeutics, gaining ownership of the cancer drug Cosela in a deal valued at over half a billion kroner. - The acquisition represents a significant expansion for Pharmacosmos, traditionally focused on iron deficiency treatments, into the oncology market with an established commercial product. - Company executives indicate they will focus on integration over the next six months, with potential for additional acquisitions in the longer term but not immediately.
- Pharmacosmos Group has successfully completed its acquisition of G1 Therapeutics for $7.15 per share, representing a 68% premium to G1's closing price before announcement and a total equity value of approximately $405 million. - The acquisition brings COSELA (trilaciclib), the first and only FDA-approved therapy for chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer patients, into Pharmacosmos' portfolio of hematology and supportive care products. - Pharmacosmos plans to leverage its global commercial presence and expertise in hematology to expand COSELA's availability beyond the US and China markets, with plans to pursue registration in the UK and EU.
